Auszug
Pharmakokinetisch wurden bisher für Maraviroc weder relevante Unterschiede zwischen Kaukasiern, Asiaten und Angehörigen der schwarzen Bevölkerung noch zwischen den Geschlechtern beobachtet.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abel S, Russell D, Ridgway C, et al. The effect of CCR5 antagonist UK-427,857, on the pharmacokinetics of CYP3A4 substrates in healthy volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy, 1–3 April, 2004 Rome
Abel S, Whitlock L, Ridgway C, Saifulanwar A, Bakhtyari, Russell D. Effect of UK-427,857 on the pharmacokinetics of oral contraceptive steroids, and the pharmacokinetics of UK-427,857 in healthy young women. ICAAC, Chicago 14—17 September, 2003
Abel S, Russell D, Ridgway C, Medhurst C, Weissgerber G, Muirhead G. Effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy, 1–3 April, 2004 Rome
Abel S et al, Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK 427,857) in healthy volunteers. 10th European AIDS Conference, Dublin. December 16–19,2005, Abstract 1200
Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions — review of the literature. Eur J Med Res 2007; 12:409–417
Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist, UK-427,857, in healthy volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy, 1–3 April, 2004 Rome
Muirhead G, Russell D, Abel S, et al. An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Seventh International Congress on Drug Therapy in HIV infection, Glasgow, UK 14–18 November 2004
Russell D, Ridgway C, Mills C, van der Merwe R, Muirhead G. A Study to investigate the combined co-administration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Seventh International Congress on Drug Therapy in HIV infection, Glasgow, UK 14–18 November 2004
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Esser, S. (2008). Maraviroc: Dosierung, Kombinationspartner und wichtige Interaktionen. In: Jäger, H. (eds) Entry Inhibitoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78358-9_16
Download citation
DOI: https://doi.org/10.1007/978-3-540-78358-9_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-78357-2
Online ISBN: 978-3-540-78358-9
eBook Packages: Medicine (German Language)